{"hands_on_practices": [{"introduction": "The clinical utility of a diagnostic test is not defined solely by its intrinsic accuracy, but by its performance in a specific patient population. This exercise will guide you through the fundamental process of calculating a test's Positive and Negative Predictive Values ($PPV$ and $NPV$) from its sensitivity, specificity, and the disease prevalence in the cohort being tested. Understanding this relationship is crucial for interpreting what a positive or negative result from a gene panel truly means for a patient [@problem_id:5085154].", "problem": "A clinical laboratory offers a targeted gene panel for a Mendelian neurodevelopmental disorder. In a referred diagnostic cohort, the disease prevalence is $p$. The panel’s analytic performance against a clinical gold standard has been established with sensitivity $Se$ and specificity $Sp$. Using only the core definitions that sensitivity is $P(\\text{test}+\\mid \\text{disease})$, specificity is $P(\\text{test}-\\mid \\text{no disease})$, prevalence is $P(\\text{disease})$, the law of total probability, and Bayes’ theorem, first derive symbolic expressions for the Positive Predictive Value (PPV), defined as $P(\\text{disease}\\mid \\text{test}+)$, and the Negative Predictive Value (NPV), defined as $P(\\text{no disease}\\mid \\text{test}-)$, in terms of $p$, $Se$, and $Sp$. Then, evaluate both expressions for a referred cohort with $p=0.30$, $Se=0.92$, and $Sp=0.985$. Report your numerical results as decimal fractions (not percents), rounded to four significant figures, in the order $PPV$, $NPV$.", "solution": "The problem requires the derivation of symbolic expressions for the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) based on fundamental principles of probability, followed by a numerical evaluation.\n\nLet's define the events:\n- $D$: The patient has the disease.\n- $D^c$: The patient does not have the disease.\n- $T+$: The test result is positive.\n- $T-$: The test result is negative.\n\nThe givens from the problem statement are translated into this notation as:\n- Prevalence: $P(D) = p$\n- Sensitivity: $Se = P(T+ \\mid D)$\n- Specificity: $Sp = P(T- \\mid D^c)$\n\nFrom these, we can state the probabilities of the complementary events:\n- $P(D^c) = 1 - P(D) = 1 - p$\n- The probability of a false negative is $P(T- \\mid D) = 1 - P(T+ \\mid D) = 1 - Se$.\n- The probability of a false positive is $P(T+ \\mid D^c) = 1 - P(T- \\mid D^c) = 1 - Sp$.\n\nThe quantities to be derived are:\n- Positive Predictive Value: $PPV = P(D \\mid T+)$\n- Negative Predictive Value: $NPV = P(D^c \\mid T-)$\n\n**1. Symbolic Derivation of PPV**\n\nThe PPV, $P(D \\mid T+)$, is the probability that a patient has the disease given a positive test result. We use Bayes' theorem to express this:\n$$PPV = P(D \\mid T+) = \\frac{P(T+ \\mid D) P(D)}{P(T+)}$$\nThe numerator terms are given: $P(T+ \\mid D) = Se$ and $P(D) = p$.\nThe denominator, $P(T+)$, is the total probability of a positive test. We find it using the law of total probability, conditioning on the disease status:\n$$P(T+) = P(T+ \\mid D) P(D) + P(T+ \\mid D^c) P(D^c)$$\nSubstituting the known terms into this expression:\n$$P(T+) = (Se)(p) + (1 - Sp)(1 - p)$$\nNow, substituting the expression for $P(T+)$ back into the formula for PPV, we obtain the symbolic expression:\n$$PPV = \\frac{Se \\cdot p}{Se \\cdot p + (1 - Sp)(1 - p)}$$\n\n**2. Symbolic Derivation of NPV**\n\nThe NPV, $P(D^c \\mid T-)$, is the probability that a patient does not have the disease given a negative test result. Applying Bayes' theorem:\n$$NPV = P(D^c \\mid T-) = \\frac{P(T- \\mid D^c) P(D^c)}{P(T-)}$$\nThe numerator terms are given or derived: $P(T- \\mid D^c) = Sp$ and $P(D^c) = 1-p$.\nThe denominator, $P(T-)$, is the total probability of a negative test. We find it using the law of total probability:\n$$P(T-) = P(T- \\mid D^c) P(D^c) + P(T- \\mid D) P(D)$$\nSubstituting the known terms:\n$$P(T-) = (Sp)(1 - p) + (1 - Se)(p)$$\nSubstituting this expression for $P(T-)$ back into the formula for NPV, we get:\n$$NPV = \\frac{Sp \\cdot (1 - p)}{Sp \\cdot (1 - p) + (1 - Se) \\cdot p}$$\n\n**3. Numerical Evaluation**\n\nWe are given the following values for a specific referred cohort:\n- $p = 0.30$\n- $Se = 0.92$\n- $Sp = 0.985$\n\nWe can also compute:\n- $1 - p = 1 - 0.30 = 0.70$\n- $1 - Se = 1 - 0.92 = 0.08$\n- $1 - Sp = 1 - 0.985 = 0.015$\n\n**Evaluation of PPV:**\nUsing the derived symbolic expression:\n$$PPV = \\frac{Se \\cdot p}{Se \\cdot p + (1 - Sp)(1 - p)} = \\frac{(0.92)(0.30)}{(0.92)(0.30) + (0.015)(0.70)}$$\n$$PPV = \\frac{0.276}{0.276 + 0.0105} = \\frac{0.276}{0.2865}$$\n$$PPV \\approx 0.963350785...$$\nRounding to four significant figures, we get $PPV = 0.9634$.\n\n**Evaluation of NPV:**\nUsing the derived symbolic expression:\n$$NPV = \\frac{Sp \\cdot (1 - p)}{Sp \\cdot (1 - p) + (1 - Se) \\cdot p} = \\frac{(0.985)(0.70)}{(0.985)(0.70) + (0.08)(0.30)}$$\n$$NPV = \\frac{0.6895}{0.6895 + 0.024} = \\frac{0.6895}{0.7135}$$\n$$NPV \\approx 0.96636300...$$\nRounding to four significant figures, we get $NPV = 0.9664$.\n\nThe final results are $PPV = 0.9634$ and $NPV = 0.9664$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.9634 & 0.9664\n\\end{pmatrix}\n}\n$$", "id": "5085154"}, {"introduction": "Classifying a novel genetic variant is a cornerstone of modern medical genetics, relying on the systematic integration of diverse evidence. This practice problem simulates the quantitative framework used by experts, where a prior probability of pathogenicity is updated using evidence-based likelihood ratios from functional, population, and computational data. By applying Bayes' theorem, you will calculate the posterior probability of pathogenicity, mimicking the logic that underpins the American College of Medical Genetics and Genomics (ACMG) variant interpretation guidelines [@problem_id:5085219].", "problem": "A clinical targeted gene panel for inherited cardiomyopathy screens $50$ established disease genes. In a proband with a compatible phenotype, the panel identifies a novel missense variant in a gene with well-established disease association. Based on the gene’s disease architecture, you adopt a calibrated prior probability of pathogenicity for any novel rare missense variant in this gene of $p_{0} = 0.06$. Three independent evidence streams are available, each with a pre-validated, evidence-based likelihood ratio calibrated from cohort data: a functional assay in induced pluripotent stem cell (iPSC) cardiomyocytes shows reproducible loss of function ($\\text{likelihood ratio from functional assay} = 14.5$), high-quality population frequency data show the variant is absent from a very large, ancestrally matched reference dataset ($\\text{likelihood ratio from population data} = 9.2$), and multiple concordant computational prediction tools support deleterious impact ($\\text{likelihood ratio from computational predictions} = 2.3$). Assume that, conditional on the true pathogenicity status of the variant, these evidence streams are independent, and that the likelihood ratios reflect $P(\\text{evidence} \\mid \\text{pathogenic}) / P(\\text{evidence} \\mid \\text{benign})$.\n\nUsing a Bayesian framework consistent with established variant interpretation practice (for example, the American College of Medical Genetics and Genomics (ACMG) evidence weighting approach), determine the posterior probability of pathogenicity for this variant from first principles. Express your final answer as a decimal and round to four significant figures.", "solution": "The problem requires the calculation of the posterior probability of pathogenicity for a novel missense variant using a Bayesian framework. The problem is valid as it is well-posed, scientifically grounded in standard principles of medical genetics and statistics, and provides all necessary information.\n\nLet $H_{path}$ be the hypothesis that the variant is pathogenic, and $H_{ben}$ be the hypothesis that the variant is benign. The problem provides a prior probability of pathogenicity, which we denote as $P(H_{path})$.\nThe given prior probability is $p_{0} = P(H_{path}) = 0.06$.\nThe prior probability of the variant being benign is therefore $P(H_{ben}) = 1 - P(H_{path}) = 1 - 0.06 = 0.94$.\n\nWe are given three independent streams of evidence. Let $E_{func}$ be the evidence from the functional assay, $E_{pop}$ be the evidence from population data, and $E_{comp}$ be the evidence from computational predictions. The total evidence is $E = E_{func} \\cap E_{pop} \\cap E_{comp}$. We wish to calculate the posterior probability $P(H_{path} \\mid E)$.\n\nAccording to Bayes' theorem, the posterior probability is given by:\n$$\nP(H_{path} \\mid E) = \\frac{P(E \\mid H_{path}) P(H_{path})}{P(E)}\n$$\nThe denominator, $P(E)$, is the total probability of observing the evidence, which can be expanded using the law of total probability:\n$$\nP(E) = P(E \\mid H_{path}) P(H_{path}) + P(E \\mid H_{ben}) P(H_{ben})\n$$\nSubstituting this into the Bayes' formula yields:\n$$\nP(H_{path} \\mid E) = \\frac{P(E \\mid H_{path}) P(H_{path})}{P(E \\mid H_{path}) P(H_{path}) + P(E \\mid H_{ben}) P(H_{ben})}\n$$\nThe problem provides likelihood ratios ($LR$) for each piece of evidence, defined as $LR = \\frac{P(\\text{evidence} \\mid H_{path})}{P(\\text{evidence} \\mid H_{ben})}$. The specific likelihood ratios are:\n-   $LR_{func} = \\frac{P(E_{func} \\mid H_{path})}{P(E_{func} \\mid H_{ben})} = 14.5$\n-   $LR_{pop} = \\frac{P(E_{pop} \\mid H_{path})}{P(E_{pop} \\mid H_{ben})} = 9.2$\n-   $LR_{comp} = \\frac{P(E_{comp} \\mid H_{path})}{P(E_{comp} \\mid H_{ben})} = 2.3$\n\nA crucial piece of information is that the evidence streams are independent, conditional on the true pathogenicity status of the variant. This allows us to find the likelihood of the combined evidence by multiplying the likelihoods of the individual pieces of evidence:\n$$\nP(E \\mid H_{path}) = P(E_{func} \\mid H_{path}) \\times P(E_{pop} \\mid H_{path}) \\times P(E_{comp} \\mid H_{path})\n$$\n$$\nP(E \\mid H_{ben}) = P(E_{func} \\mid H_{ben}) \\times P(E_{pop} \\mid H_{ben}) \\times P(E_{comp} \\mid H_{ben})\n$$\nThis means we can also calculate a combined likelihood ratio, $LR_{total}$, by multiplying the individual likelihood ratios:\n$$\nLR_{total} = \\frac{P(E \\mid H_{path})}{P(E \\mid H_{ben})} = LR_{func} \\times LR_{pop} \\times LR_{comp}\n$$\nPlugging in the given values:\n$$\nLR_{total} = 14.5 \\times 9.2 \\times 2.3 = 133.4 \\times 2.3 = 306.82\n$$\nNow, we can simplify the expression for the posterior probability by dividing the numerator and the denominator by $P(E \\mid H_{ben})$:\n$$\nP(H_{path} \\mid E) = \\frac{\\frac{P(E \\mid H_{path})}{P(E \\mid H_{ben})} P(H_{path})}{\\frac{P(E \\mid H_{path})}{P(E \\mid H_{ben})} P(H_{path}) + P(H_{ben})}\n$$\nSubstituting $LR_{total}$, $P(H_{path})$, and $P(H_{ben})$:\n$$\nP(H_{path} \\mid E) = \\frac{LR_{total} \\times P(H_{path})}{LR_{total} \\times P(H_{path}) + P(H_{ben})}\n$$\nNow, we substitute the numerical values into this expression:\n$$\nP(H_{path} \\mid E) = \\frac{306.82 \\times 0.06}{(306.82 \\times 0.06) + (1 - 0.06)}\n$$\nFirst, calculate the numerator:\n$$\n306.82 \\times 0.06 = 18.4092\n$$\nNext, calculate the denominator:\n$$\n18.4092 + 0.94 = 19.3492\n$$\nFinally, calculate the posterior probability:\n$$\nP(H_{path} \\mid E) = \\frac{18.4092}{19.3492} \\approx 0.95141908\n$$\nThe problem requires the answer to be expressed as a decimal rounded to four significant figures. The first four significant figures are $9$, $5$, $1$, and $4$. The fifth digit is $1$, so we round down.\n$$\nP(H_{path} \\mid E) \\approx 0.9514\n$$\nThe information that the targeted gene panel screens $50$ genes is contextual and not required for the calculation, as a specific prior probability for the variant in the gene of interest was provided.", "answer": "$$\\boxed{0.9514}$$", "id": "5085219"}, {"introduction": "Interpreting sequencing data from tumors presents unique challenges, as the sample is a mixture of cancerous and normal cells. In this exercise, you will learn to deconstruct the observed variant allelic fraction ($a$) to infer the true state of the variant within the tumor cells, accounting for both tumor purity ($P$) and the local copy number state. This practice is essential for understanding tumor heterogeneity and correctly interpreting somatic variant calls in oncology [@problem_id:5085189].", "problem": "A targeted gene panel assay of a solid tumor reports an observed variant allelic fraction (also called allelic fraction) of $a=0.30$ for a single-nucleotide variant at a locus where independent copy-number analysis shows copy-neutral Loss of Heterozygosity (LOH) in tumor cells. The tumor purity is $P=0.50$ (tumor cell proportion in the sequenced specimen). Assume the following, consistent with standard mixture models in somatic variant interpretation:\n\n- Normal cells are diploid with total copy number $2$ at the locus and contribute no mutant alleles.\n- Tumor cells are copy-neutral LOH at this locus, so their total copy number is $2$ and both copies derive from the same parental haplotype.\n- The variant is present in a fraction $c$ (unknown) of tumor cells. In any tumor cell that harbors the variant, the number of mutant copies at the locus is $m \\in \\{1,2\\}$, corresponding to heterozygous ($m=1$) or homozygous ($m=2$) state within that tumor cell.\n- Sequencing is unbiased with respect to allele and cell type, and the observed allelic fraction equals the ratio of the expected number of mutant allele copies to the expected total number of allele copies in the sequenced mixture.\n\nStarting from these assumptions and the definition of allelic fraction as mutant copies divided by total copies in the mixture, derive an expression for $a$ in terms of $P$, $c$, and $m$, then use $a=0.30$ and $P=0.50$ to determine the implied clonal cell fraction $c$ and the compatible zygosity code $z$, where $z=1$ for heterozygous and $z=2$ for homozygous. If multiple $m$ values are mathematically possible, enforce the biological constraint $0 \\leq c \\leq 1$ to choose the compatible case.\n\nRound the clonal cell fraction $c$ to three significant figures. Report your final answer as a $1 \\times 2$ row matrix containing $c$ and $z$, in that order. No units are required.", "solution": "We begin from the definition of observed allelic fraction as the ratio of mutant allele copies to total allele copies in the sequenced mixture, under an assumption of unbiased sampling. Let $a$ denote the observed allelic fraction, $P$ the tumor purity (fraction of tumor cells in the sample), $c$ the fraction of tumor cells that harbor the variant, and $m$ the number of mutant copies in each variant-harboring tumor cell.\n\nBy assumption, normal cells are diploid at this locus and contribute no mutant alleles. Tumor cells are also total copy number $2$ due to copy-neutral Loss of Heterozygosity (LOH). Therefore, the expected total number of allele copies per unit cell in the mixture is the sum of tumor and normal contributions:\n$$\n\\text{total copies} = P \\cdot 2 + (1-P) \\cdot 2 = 2.\n$$\nThe expected number of mutant allele copies per unit cell in the mixture comes only from tumor cells that harbor the variant. A fraction $c$ of tumor cells carry the variant, and in each such tumor cell there are $m$ mutant copies. Thus,\n$$\n\\text{mutant copies} = P \\cdot c \\cdot m.\n$$\nTherefore, by the definition of allelic fraction,\n$$\na = \\frac{\\text{mutant copies}}{\\text{total copies}} = \\frac{P \\cdot c \\cdot m}{2}.\n$$\nSolving for the product $c \\cdot m$ gives\n$$\nc \\cdot m = \\frac{2a}{P}.\n$$\nWith $a=0.30$ and $P=0.50$,\n$$\nc \\cdot m = \\frac{2 \\cdot 0.30}{0.50} = \\frac{0.60}{0.50} = 1.2.\n$$\nWe must choose $m \\in \\{1,2\\}$ and a corresponding $c$ satisfying $0 \\leq c \\leq 1$:\n\n- If $m=1$ (heterozygous within tumor cells), then $c = 1.2$, which violates the biological constraint $c \\leq 1$ and is therefore incompatible.\n- If $m=2$ (homozygous within tumor cells), then $c = \\frac{1.2}{2} = 0.6$, which satisfies $0 \\leq c \\leq 1$ and is therefore compatible.\n\nCopy-neutral Loss of Heterozygosity (LOH) allows $m=2$ when the mutant allele is the duplicated allele or when the mutation predates the duplication; conversely, $m=1$ would require $c>1$ to explain the observed allelic fraction under the given purity and is thus excluded.\n\nHence, the implied clonal cell fraction is $c=0.6$ and the compatible zygosity code is $z=2$ (homozygous). Rounding $c$ to three significant figures yields $c=0.600$.\n\nWe report the result as a $1 \\times 2$ row matrix containing $c$ and $z$ in that order.", "answer": "$$\\boxed{\\begin{pmatrix} 0.600 & 2 \\end{pmatrix}}$$", "id": "5085189"}]}